Prescribing information

 

Tools and resources for healthcare professionals to support the use of Xolair in day‑to‑day practice.

With the exception of the video resources, these items are available in print format. To order printed materials, please contact your local key account manager.

Image of stethoscope and iPad on a desk
 

DOSING AND SELF-ADMINISTRATION RESOURCES

From dosing guidance for healthcare professionals to how-to videos for patients, these resources are designed to make the transition to administration at home as smooth as possible.

See more

mode of action video
 

MODE OF ACTION VIDEO

Watch the video to learn more about Xolair’s highly specific mode of action, which targets both phases of the asthmatic response.

Watch

patient forms
 

PATIENT FORMS

These forms are designed to help you identify patients that have SAA and may be suitable for treatment with Xolair, and to help you assess response.

View

 
 

Image of stethoscope and iPad on a desk
 

ADMINISTRATION POSTER

This poster illustrates step-by-step instructions for healthcare professionals administering Xolair.

View

Novartis' Severe Asthma Masterclass is a multidisciplinary educational programme that has been running for 12 years and brings together expertise from across the UK to provide high-quality educational content to help improve your clinical practice in severe asthma.
 

Below you can view some of the presentations from our Masterclass meeting in 2019 and our first Masterclass webinar from July 2020.

 

e in p logo
 

ALLERGIC ASTHMA – DO WE GET IT RIGHT? (VIDEO)
 

ALLERGIC ASTHMA – DO WE GET IT RIGHT? (VIDEO)

Speaking at the 2019 Severe Asthma Masterclass, Dr Robin Gore discusses recent progress in severe allergic asthma, our current understanding of the disease, and the importance of having the right tools to evaluate patients.
 

Watch

 

REFLUX AND ASTHMA – WHAT IS THE RELATIONSHIP? (VIDEO)
 

REFLUX AND ASTHMA – WHAT IS THE RELATIONSHIP? (VIDEO)

Speaking at the 2019 Severe Asthma Masterclass, Prof. Alyn Morice discusses the relationship between oesophageal diseases, such as cough hypersensitivity syndrome, and the treatment of asthma.
 

Watch

 

ALLERGEN AVOIDANCE – ARE WE GETTING IT RIGHT? (VIDEO)
 

ALLERGEN AVOIDANCE – ARE WE GETTING IT RIGHT? (VIDEO)

Speaking at the 2019 Paediatric Severe Asthma Masterclass, Dr Clare Murray discusses the role of allergen exposure in children with asthma, and whether avoidance strategies can be used to improve asthma control.
 

Watch

 


 
 

COVID-19 AND SEVERE ASTHMA (VIDEO)
 

COVID-19 AND SEVERE ASTHMA (VIDEO)

In this 2020 webinar, Prof. Andrew Menzies-Gow discusses the lessons learned from the COVID-19 pandemic and how we can use these to improve severe asthma services in the future. This is followed by an expert panel discussion chaired by Dr Rob Niven and including Prof. Andrew Menzies-Gow, Rachel Stead and Dr Helen Hope.
 

Watch

 

YOUR XOLAIR DIARY
 

YOUR XOLAIR DIARY

This booklet allows patients to track their symptoms in the first 16 weeks of treatment with Xolair, helping healthcare professionals assess the effectiveness of Xolair for that patient.

View

YOUR QUESTIONS ANSWERED
 

YOUR QUESTIONS ANSWERED

This booklet is for patients prescribed Xolair to help them understand more about SAA and what to expect from their treatment.

View

 

 

 

*Xolair provides clinically meaningful improvements in quality of life for patients with severe allergic asthma.1

Indication2: Xolair should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma. In adults and adolescents (12 years of age and older): Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 <80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. In children (6 to <12 years of age): Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.

FEV1, forced expiratory volume in 1 second; IgE, immunoglobulin E; SAA, severe allergic asthma.

References

  1. Braunstahl GJ et al. Resp Med 2013;107(8):1141–1151.
  2. Xolair® (omalizumab) Summary of Product Characteristics.
XSA20-C028(1) September 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]